To build its ophthalmology portfolio, Japan’s Otsuka Pharmaceuticals has teamed with RNA editing biotech Shape Therapeutics to develop adeno-associated virus gene therapies for ocular diseases.

A team involving researchers from Alcediag, Montpellier University Hospital, Les Toises Psychiatry Centre in Lausanne and Professor David J. Kupfer from the University of Pittsburgh identified and validated a combination of blood biomarkers specific to bipolar disorder. These results, recently published in the leading scientific journal Nature, have led to the development of the first diagnostic blood test for this disorder that affects more than 60 million people worldwide.